|
1
|
Rizzo S, Cangemi A, Galvano A, Fanale D,
Buscemi S, Ciaccio M, Russo A, Castorina S and Bazan V: Analysis of
miRNA expression profile induced by short term starvation in breast
cancer cells treated with doxorubicin. Oncotarget. 8:71924–71932.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mandujano-Tinoco EA, Garcia-Venzor A,
Muñoz-Galindo L, Lizarraga-Sanchez F, Favela-Orozco A,
Chavez-Gutierrez E, Krötzsch E, Salgado RM, Melendez-Zajgla J and
Maldonado V: miRNA expression profile in multicellular breast
cancer spheroids. Biochim Biophys Acta. 1864:1642–1655. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li P, Xu T, Zhou X, Liao L, Pang G, Luo W,
Han L, Zhang J, Luo X, Xie X and Zhu K: Downregulation of miRNA-141
in breast cancer cells is associated with cell migration and
invasion: Involvement of ANP32E targeting. Cancer Med. 6:662–672.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lykov AP, Kabakov AV, Kazakov OV,
Bondarenko NA, Poveshchenko OV, Raiter TV, Poveshchenko AF,
Strunkin DN and Konenkov VI: Levels of miRNA and hormones in
thoracic duct lymph in rats with experimental breast cancer induced
by N-methyl-N-nitrosourea. Bull Exp Biol Med. 162:387–390. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bhardwaj A, Singh H, Rajapakshe K,
Tachibana K, Ganesan N, Pan Y, Gunaratne PH, Coarfa C and Bedrosian
I: Regulation of miRNA-29c and its downstream pathways in
preneoplastic progression of triple-negative breast cancer.
Oncotarget. 8:19645–19660. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Danza K, Summa S, Pinto R, Pilato B,
Palumbo O, Carella M, Popescu O, Digennaro M, Lacalamita R and
Tommasi S: TGFbeta and miRNA regulation in familial and sporadic
breast cancer. Oncotarget. 8:50715–50723. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fang H, Xie J, Zhang M, Zhao Z, Wan Y and
Yao Y: miRNA-21 promotes proliferation and invasion of
triple-negative breast cancer cells through targeting PTEN. Am J
Transl Res. 9:953–961. 2017.PubMed/NCBI
|
|
8
|
Zhang L, Xu J, Yang G, Li H and Guo X:
miR-202 inhibits cell proliferation, migration, and invasion by
targeting EGFR in human bladder cancer. Oncol Res. Jan 3–2018.(Epub
ahead of print). View Article : Google Scholar
|
|
9
|
Kim RK, Suh Y, Yoo KC, Cui YH, Kim H, Kim
MJ, Kim Gyu I and Lee SJ: Activation of KRAS promotes the
mesenchymal features of basal-type breast cancer. Exp Mol Med.
47:e1372015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim Y, Kim J, Lee HD, Jeong J, Lee W and
Lee KA: Spectrum of EGFR gene copy number changes and KRAS gene
mutation status in Korean triple negative breast cancer patients.
PLoS One. 8:e790142013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McVeigh TP, Jung SY, Kerin MJ, Salzman DW,
Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, et
al: Estrogen withdrawal, increased breast cancer risk and the
KRAS-variant. Cell Cycle. 14:2091–2099. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Su X, Zhang L, Li H, Cheng P, Zhu Y, Liu
Z, Zhao Y, Xu H, Li D, Gao H and Zhang T: MicroRNA-134 targets KRAS
to suppress breast cancer cell proliferation, migration and
invasion. Oncol Lett. 13:1932–1938. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zeng Y, Zhou Z, Fan M, Gong T, Zhang Z and
Sun X: PEGylated cationic vectors containing a protease-sensitive
peptide as a miRNA delivery system for treating breast cancer. Mol
Pharm. 14:81–92. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang J, Le TD, Liu L and Li J: Inferring
miRNA sponge co-regulation of protein-protein interactions in human
breast cancer. BMC Bioinformatics. 18:2432017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang L, Yang X, Lv Y, Xin X, Qin C, Han
X, Yang L, He W and Yin L: Cytosolic co-delivery of miRNA-34a and
docetaxel with core-shell nanocarriers via caveolae-mediated
pathway for the treatment of metastatic breast cancer. Sci Rep.
7:461862017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao Z, Lv B, Zhang L, Zhao N and Lv Y:
miR-202 functions as a tumor suppressor in non-small cell lung
cancer by targeting STAT3. Mol Med Rep. 16:2281–2289. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mody HR, Hung SW, Pathak RK, Griffin J,
Cruz-Monserrate Z and Govindarajan R: miR-202 diminishes TGFβ
receptors and attenuates TGFβ1-Induced EMT in pancreatic cancer.
Mol Cancer Res. 15:1029–1039. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Y, Chen Z, Li MJ, Guo HY and Jing
NC: Long non-coding RNA metastasis-associated lung adenocarcinoma
transcript 1 regulates the expression of Gli2 by miR-202 to
strengthen gastric cancer progression. Biomed Pharmacother.
85:264–271. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yi Y, Li H, Lv Q, Wu K and Zhang W, Zhang
J, Zhu D, Liu Q and Zhang W: miR-202 inhibits the progression of
human cervical cancer through inhibition of cyclin D1. Oncotarget.
7:72067–72075. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Farhana L, Dawson MI and Fontana JA: Down
regulation of miR-202 modulates Mxd1 and Sin3A repressor complexes
to induce apoptosis of pancreatic cancer cells. Cancer Biol Ther.
16:115–124. 2016. View Article : Google Scholar
|
|
21
|
Joosse SA, Müller V, Steinbach B, Pantel K
and Schwarzenbach H: Circulating cell-free cancer-testis MAGE-A
RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with
breast cancer and benign breast diseases. Br J Cancer. 111:909–917.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao Y, Li C, Wang M, Su L, Qu Y, Li J, Yu
B, Yan M, Yu Y, Liu B and Zhu Z: Decrease of miR-202-3p expression,
a novel tumor suppressor, in gastric cancer. PLoS One.
8:e697562013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cejalvo JM, Pérez-Fidalgo JA, Ribas G,
Burgués O, Mongort C, Alonso E, Ibarrola-Villava M, Bermejo B,
Martínez MT, Cervantes A and Lluch A: Clinical implications of
routine genomic mutation sequencing in PIK3CA/AKT1 and
KRAS/NRAS/BRAF in metastatic breast cancer. Breast Cancer Res
Treat. 160:69–77. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ustinova M, Daneberga Z, Bērziņa D,
Nakazawa-Miklaševiča M, Maksimenko J, Gardovskis J and Miklaševičs
E: Impact of KRAS variant rs61764370 on breast cancer morbidity.
Exp Oncol. 37:292–294. 2015.PubMed/NCBI
|
|
25
|
Huang X, Yang Y, Guo Y, Cao ZL, Cui ZW, Hu
TC and Gao LB: Association of a let-7 KRAS rs712 polymorphism with
the risk of breast cancer. Genet Mol Res. 14:16913–16920. 2015.
View Article : Google Scholar : PubMed/NCBI
|
